文献速递肿瘤 PET/CT核素与放射性配体治疗

不同影像方法可能影响接受转移灶定向治疗的寡复发前列腺癌患者的长期肿瘤学结局(PRECISE-MDT研究)

Diverse Imaging Methods May Influence Long-Term Oncologic Outcomes in Oligorecurrent Prostate Cancer Patients Treated with Metastasis-Directed Therapy (the PRECISE-MDT Study).
PubMed 文献 · J Nucl Med · 2024-08-01

该回顾性研究纳入8家三级癌症中心的402例寡复发前列腺癌患者,比较胆碱PET/CT与PSMA PET/CT引导的转移灶定向治疗(MDT)的长期结局。倾向评分匹配后,PSMA PET/CT引导组无进展生存期、至因多转移转化而更换系统治疗的时间及总生存期均优于胆碱PET/CT引导组。作者认为不同影像方法可能影响MDT结局,但需前瞻性头对头研究(最好采用随机设计)提供确证证据。

要点

  • 倾向评分匹配后,PSMA PET/CT引导MDT较胆碱PET/CT引导MDT的PFS更长(HR 0.49,95%CI 0.36-0.67)。
  • 匹配后PSMA PET/CT引导组PFS2(HR 0.42,95%CI 0.28-0.63)和OS(HR 0.39,95%CI 0.15-0.99)均优于胆碱组。
  • 匹配后[68Ga]Ga-PSMA-11较[18F]F-PSMA-1007引导MDT的PFS和PFS2更长。

核心结论

  • 不同影像方法可能影响接受MDT的寡复发前列腺癌患者的结局。
  • 作者认为需要前瞻性头对头研究、最好采用随机设计,以提供确证证据并促进这些发现的临床应用。

研究设计与样本

  • 回顾性识别8家三级癌症中心中经胆碱或PSMA PET/CT检出≤5个淋巴结、骨或内脏转移的寡复发前列腺癌患者。
  • 患者接受MDT立体定向体部放疗,伴或不伴系统治疗。
  • 采用倾向评分匹配校正组间临床差异。
  • 共纳入402例患者,其中232例(57.7%)接受[18F]氟胆碱PET/CT引导MDT,170例(42.3%)接受PSMA PET/CT引导MDT。

主要发现

  • 倾向评分匹配后,PSMA PET/CT引导MDT组较胆碱PET/CT引导MDT组PFS更长(HR 0.49,95%CI 0.36-0.67;P<0.0001)。
  • 匹配后PSMA PET/CT引导组较胆碱组PFS2更长(HR 0.42,95%CI 0.28-0.63;P<0.0001)。
  • 匹配后PSMA PET/CT引导组较胆碱组OS更长(HR 0.39,95%CI 0.15-0.99;P<0.05)。
  • 匹配[68Ga]Ga-PSMA-11与[18F]F-PSMA-1007 PET/CT引导MDT患者后,前者PFS更长(HR 0.51,95%CI 0.26-1.00;P<0.05)。
  • 匹配后[68Ga]Ga-PSMA-11组较[18F]F-PSMA-1007组PFS2更长(HR 0.24,95%CI 0.09-0.60;P<0.05)。

关键数值与推荐

  • 寡复发前列腺癌定义为胆碱或PSMA PET/CT检出≤5个淋巴结、骨或内脏转移。
  • MDT为立体定向体部放疗,可伴或不伴系统治疗。
  • PSMA PET/CT引导MDT较胆碱PET/CT引导MDT的PFS:HR 0.49(95%CI 0.36-0.67;P<0.0001)。
  • PSMA PET/CT引导MDT较胆碱PET/CT引导MDT的PFS2:HR 0.42(95%CI 0.28-0.63;P<0.0001)。
  • PSMA PET/CT引导MDT较胆碱PET/CT引导MDT的OS:HR 0.39(95%CI 0.15-0.99;P<0.05)。

临床怎么用

  • 原文未据此给出推荐。
  • 作者结论指出不同影像方法可能影响接受MDT的寡复发前列腺癌患者结局。

局限性

  • 作者指出需要前瞻性头对头研究、最好采用随机设计,以提供确证证据并促进这些发现的临床应用。
  • 原文未报告其他局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Metastasis-directed therapy (MDT) has been tested in clinical trials as a treatment option for oligorecurrent prostate cancer (PCa). However, there is an ongoing debate regarding the impact of using different imaging techniques interchangeably for defining lesions and guiding MDT within clinical trials. Methods: We retrospectively identified oligorecurrent PCa patients who had 5 or fewer nodal, bone, or visceral metastases detected by choline or prostate-specific membrane antigen (PSMA) PET/CT and who underwent MDT stereotactic body radiotherapy with or without systemic therapy in 8 tertiary-level cancer centers. Imaging-guided MDT was assessed as progression-free survival (PFS), time to systemic treatment change due to polymetastatic conversion (PFS2), and overall survival predictor. Propensity score matching was performed to account for clinical differences between groups. Results: Of 402 patients, 232 (57.7%) and 170 (42.3%) underwent MDT guided by [18F]fluorocholine and PSMA PET/CT, respectively. After propensity score matching, patients treated with PSMA PET/CT-guided MDT demonstrated longer PFS (hazard ratio [HR], 0.49 [95% CI, 0.36-0.67]; P < 0.0001), PFS2 (HR, 0.42 [95% CI, 0.28-0.63]; P < 0.0001), and overall survival (HR, 0.39 [95% CI, 0.15-0.99]; P < 0.05) than those treated with choline PET/CT-guided MDT. Additionally, we matched patients who underwent [68Ga]Ga-PSMA-11 versus [18F]F-PSMA-1007 PET/CT, observing longer PFS and PFS2 in the former subgroup (PFS: HR, 0.51 [95% CI, 0.26-1.00]; P < 0.05; PFS2: HR, 0.24 [95% CI, 0.09-0.60]; P < 0.05). Conclusion: Diverse imaging methods may influence outcomes in oligorecurrent PCa patients undergoing MDT. However, prospective, head-to-head studies, ideally incorporating a randomized design, are necessary to provide definitive evidence and facilitate the practical application of these findings.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Bauckneht M, Lanfranchi F, Albano D, et al. Diverse Imaging Methods May Influence Long-Term Oncologic Outcomes in Oligorecurrent Prostate Cancer Patients Treated with Metastasis-Directed Therapy (the PRECISE-MDT Study). J Nucl Med. 2024. PMID: 38906557. doi:10.2967/jnumed.124.267586

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。